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Abstract Huntington’s disease (HD) is a neurodegenera-
tive genetic disorder that affects the brain. Atrophy of deep
grey matter structures has been reported and it is likely
that underlying pathologic processes occur before, or in
concurrence with, volumetric changes. Measurement of
metabolite concentrations in these brain structures has the
potential to provide insight into pathological processes. We
aim to gain understanding of metabolite changes with
respect to the disease stage and pathophysiological changes.
We studied ﬁve brain regions using magnetic resonance
spectroscopy (MRS) using a 7-Tesla MRI scanner. Local-
ized proton spectra were acquired to obtain six metabolite
concentrations. MRS was performed in the caudate nucleus,
putamen, thalamus, hypothalamus, and frontal lobe in 44
control subjects, premanifest gene carriers and manifest
HD. In the caudate nucleus, HD patients display lower NAA
(p = 0.009) and lower creatine concentration (p = 0.001)
as compared to controls. In the putamen, manifest HD
patients show lower NAA (p = 0.024), lower creatine
concentration (p = 0.027), and lower glutamate (p =
0.013). Although absolute values of NAA, creatine, and
glutamate were lower, no signiﬁcant differences to controls
were found in the premanifest gene carriers. The lower
concentrations of NAA and creatine in the caudate nucleus
and putamen of early manifest HD suggest deﬁcits in neu-
ronal integrity and energy metabolism. The changes in
glutamate could support the excitotoxicity theory. These
ﬁndings not only give insight into neuropathological
changes in HD but also indicate that MRS can possibly
be applied in future clinical trails to evaluate medication
targeted at speciﬁc metabolic processes.
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Abbreviations
AU Arbitrary units
BDI-II Beck Depression Inventory 2nd version
CAG Cytosine–adenine–guanine
DART Dutch Adult Reading Test
FWHM Full width half maximum
Glx Glutamate ? glutamine
HD Huntington’s disease
MMSE Mini Mental State Exam
NAA N-acetylaspartate
PMGC Premanifest gene carrier
STEAM Stimulated echo acquisition mode
TFC Total functional capacity
TMS Total motor score
UHDRS Uniﬁed Huntington’s Disease Rating Scale
Introduction
Huntington’s disease (HD) is a neurodegenerative autoso-
mal dominant disorder. The causative gene mutation is
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an expanded cytosine–adenine–guanine (CAG)-repeat
within the Htt-gene. This expansion results in the synthesis
of an abnormal huntingtin protein that causes neuronal
damage, brain atrophy, and ultimately leading to functional
disturbances of motor, cognition, and behavior.
HD research has revealed widespread changes
throughout the brain [5]. Controversy remains as to which
structures are affected at different disease stages. Atrophy
of the striatum is regarded as the hallmark of the pathologic
ﬁndings in HD [22]. MRI studies demonstrate that the
caudate nucleus and putamen begin to show atrophy up to a
decade before clinical manifestations occur [2, 29, 34].
Structures such as the thalamus, hypothalamus, the frontal
lobe, white matter, and cortical grey matter have all been
implicated to some degree at this pre-manifest stage,
although ﬁndings differ [1, 3, 5, 18].
The pathophysiological mechanism leading to neuronal
damage remains unclear. Currently, the two most accepted
hypotheses describe impaired energy metabolism and the
excitotoxicity of neurons [8, 23]. Both hypotheses can
potentially be explored by means of non-invasive in vivo
measurements of metabolites such as creatine and gluta-
mate, using localized magnetic resonance spectroscopy
(MRS). However, previous studies measuring the changes
in the metabolite levels related to the damaging processes
in HD have reported conﬂicting results. In one study, a
lower level of N-acetylaspartate (NAA) was conﬁrmed
post-mortem in the putamen and cortex in manifest HD [7].
In vivo altered levels of NAA, creatine, choline, and glu-
tamate have been reported in both premanifest and mani-
fest HD in several brain structures, such as the striatum and
thalamus using MRS [9, 11, 12, 24, 25, 31, 32]. However,
in contrast, other studies using localized MRS did not
detect changes in these metabolite levels in either manifest
or premanifest HD [6, 21, 35].
One of the factors that might explain discrepancies
between previous studies is the relatively poor spatial
and/or spectral resolution of localized spectra. Improve-
ment in MRS methodology in terms of spectral resolution
in combination with small voxel size and total scanning
time can be achieved using a high-ﬁeld MRI scanner
[14, 33]. This allows metabolite quantiﬁcation in small,
well-deﬁned anatomical structures, such as the caudate
nucleus and putamen.
The major aims of the present study were to assess
metabolite differences between manifest HD patients or
premanifest HD gene carriers and controls and to assess
the association between these metabolite differences and
clinical measures of disease severity in order to obtain a
greater understanding of the pathophysiological changes
in HD with respect to the disease stage. The hypotheses
were as follows; as the neuronal integrity and the energy
metabolism would be compromised, we expected the
NAA and creatine to be lower in premanifest and manifest
HD, especially in the striatum. Possible changes in glu-
tamate could be expected based on the excitotoxicity
theory, with higher levels in both premanifest and mani-
fest HD.
Materials and methods
Subjects
Participants were recruited from the outpatient neurology
clinic of the Leiden University Medical Center. Inclusion
criteria for the early manifest HD consisted of genetic
conﬁrmation with a CAG repeat C39, and the presence of
motor disturbances as measured by the Uniﬁed Hunting-
ton’s Disease Rating Scale ’99 (UHDRS) deﬁned as a total
motor score (TMS) [5 and a total functional capacity
(TFC) C7. All participants received a diagnostic conﬁ-
dence rating of 4, representing ‘‘motor abnormalities that
are unequivocal signs of HD (C99% conﬁdence)’’. Inclu-
sion criteria for the premanifest HD participants consisted
of genetic conﬁrmation with a CAG repeat C39, and the
absence of motor disturbances on the UHDRS deﬁned as a
TMS B5. Healthy gene-negative family members or part-
ner/spouses were recruited as control subjects in an effort
to reduce inﬂuences of environmental factors. Exclusion
criteria for all participants consisted of signiﬁcant (neuro-
logical) comorbidity, a major psychiatric diagnosis, history
of severe head injury, or incompatibility for MRI. In total,
44 subjects were recruited to undergo MRS in one or more
regions of interest (ROI). Time constraints and HD-related
issues (such as patient motion) accounted for not all par-
ticipants completing the MRS protocol in all ﬁve of the
ROIs. The study was approved by the local Medical Ethical
Committee of the Leiden University Medical Center. All
participants provided written informed consent to partici-
pate in the study.
Clinical measures
Clinical evaluation for all subjects consisted of the UHDRS
motor scale (score 0–124) and TFC, a global scale of
impairment in daily life activities, score 0–13. Further-
more, a short cognitive battery was administered consisting
of the Mini Mental State Exam (MMSE), Stroop test word
reading card (Stoop-II), the Symbol Digit Modality Test
(SDMT), Trail making Test part B (TMT-B), the Wechsler
Memory Scale (MQ) and premorbid IQ estimation using
the Dutch Adult Reading Test (DART) [26]. Behavioral
disturbances were evaluated with the Beck Depression
Inventory 2nd version (BDI-II) [4] and the Problem
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123Behaviour Assessment short version (PBA-s). Predicted
years to onset were calculated from current age and CAG
repeat length using the formula by Langbehn et al. [13].
MRI/MRS acquisition
MRI and MRS were performed on a Philips 7-Tesla
Achieva whole-body scanner (Philips Healthcare, Best,
The Netherlands) with a NOVA Medical quadrature
transmit coil and 16-channel receive coil array. For accu-
rate planning, a high-resolution, three-dimensional T1-
weighted GRE scan was acquired (TR/TE = 11/5.4 ms,
voxel size 0.44 9 0.44 9 0.84 mm, total scan time 1:46).
Localized proton spectra were acquired using a stimulated
echo acquisition mode (STEAM) sequence. The voxel was
placed within the region of interest with the maximum
volume containing only tissue from the intended structure,
minimizing the contribution from surrounding tissue and
also partial volume effects. Regions of interest consisted of
the caudate nucleus, putamen, thalamus, hypothalamus,
and the prefrontal white and cortical grey matter. For the
prefrontal voxel, positioning included approximately 50%
white and 50% cortical grey matter. Only for the hypo-
thalamus voxel was some cerebral spinal ﬂuid (CSF) nec-
essarily present since the voxel was placed bilaterally. For
each voxel in each ROI, a water reference signal was
acquired for adequate quantiﬁcation. The following scan
parameters were used for the STEAM spectra: TR/TE/
TM = 2,000/19/25 ms, BW 4 kHz, 2,048 complex data
points and 128 signal averages, giving a data acquisition
time of approximately 5 min per spectrum. The chemical
shift artifact was minimal (\1 mm), which is shown in
Fig. 1. Water suppression was performed using a fre-
quency-selective RF pulse and gradient spoiling, and six
saturation bands were additionally applied to suppress the
signal from the surrounding tissue. All scans included a
reference scan without water suppression for quantiﬁca-
tion. When an MRS scan failed (for example due to
motion), it was standard protocol to try the same ROI
again: however, in some cases this resulted in insufﬁcient
time for the full protocol to be completed, since the time
for each patient in the magnet was strictly limited to 1 h.
MRS post-processing
MRS data were analyzed with LCModel [19, 20] using the
unsuppressed water as an internal reference to calculate the
concentrations of metabolites. Concentrations of choline,
creatine, glutamine ? glutamate (Glx), total NAA (N-
acetylaspartylglutamate ? NAA), myo-inositol and lactate
were calculated for analysis.
Stringent quality control was enforced to exclude data
with high estimated errors. A signal-to-noise ratio of B3
and very high values of residual errors in the LCModel
ﬁtting were applied as initial spectral exclusion criteria.
Furthermore, the LCModel ﬁt for metabolites was required
to have a Crame ´r–Rao lower bound (CRLB) of 20% or
less. This was required for all metabolites within a single
spectrum, with the exception of lactate. For lactate, CRLB
above 100% were excluded from further analysis. If lactate
was not quantiﬁed with CRLB\100% in at least 50% of
analyzed spectra, the analysis of lactate was deemed not
detectable; this method was ﬁrst presented by Tkac et al.
[33].
In total, 30 spectra were included in the analysis for the
hypothalamus, 36 of the thalamus, 28 of the caudate
nucleus, 27 of the putamen, and 32 subjects of the pre-
frontal region.
Statistics
Statistical analyses were performed using SPSS for Win-
dows (version 17.0, SPSS Inc, Chicago, IL, USA). All
clinical variables were assessed between groups with a
one-way analysis of variance (ANOVA), with post hoc
testing. To compare all metabolites in the ﬁve brain regions
between the manifest and premanifest HD group versus the
control group, an ANOVA with planned comparisons was
performed. The nature of this study is exploratory, and
therefore in order to prevent inﬂation of type II errors and
avoid important results going unreported, no correction for
multiple testing was performed, as is accepted practice in
such types of study [17]. To examine the relationship
between metabolic concentrations and clinical measures in
gene carriers (manifest and premanifest HD), partial
Pearson correlation analysis corrected for age was
performed.
Results
Demographics
No differences in age, education level, or IQ were present
between the manifest HD and control group, or between the
premanifest HD and control group. No signiﬁcant differ-
ence exists in CAG repeat length between the premanifest
and the manifest HD group. For all other clinical assess-
ments variables, we refer to the results in Table 1.
Voxel planning
Typical examples of localized proton spectra for the ﬁve
examined regions, along with metabolite identiﬁcation, are
shown in Fig. 2. The voxel location is shown on the left
side. For clarity, the voxel is only shown in one orientation.
2232 J Neurol (2011) 258:2230–2239
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all three dimensions. Figure 3 provides a typical example
spectrum and ﬁt from the LCmodel.
Voxel sizes were individually set based upon the dif-
ferent sizes of structures in different individuals, although
the voxel size was never below 1.0 ml. With these sizes, it
was possible in all cases to include only the intended (grey
matter) structure, without contamination of other (white
matter) structures, the exception being the prefrontal
region. The voxel size ranged from 1.0 ml in the caudate
nucleus for a manifest HD participant to a maximum of
3.4 ml for the putamen of a participant in the control group.
Metabolite analysis
The concentrations of the six metabolites (NAA, creatine,
choline, glutamate, lactate, and myo-inositol) in the ﬁve
brain regions are shown in Table 2 for the three groups. In
Fig. 1 Chemical shift at
7-Tesla using STEAM.
Chemical shifts provided for an
actual planning. Red box NAA,
white box metabolite as stated
below each ﬁgure. Only a
minimal chemical shift exists.
The chemical shift of water is
almost zero, as the separate
water ﬁle is planned according
to the NAA-voxel. NAA N-
acetylaspartate
Table 1 Demographic variables and scores on clinical assessments for the three groups
Control n:1 8( #:9$: 9) Premanifest n:1 4( #:6$: 8) Manifest n:12 (#:5$:7 )
Mean SD Mean SD Mean SD
Age 47.7 7.4 42.9 11.0 48.6 7.0
Years of education 15.9 3.2 14.3 3.3 15.3 2.7
IQ 106.7 7.8 102.2 12.5 102.3 9.5
CAG 20.3
c 2.9 43.1 3.4 43.7 2.3
Disease burden na na 306.4 87.0 385.4
e 72.5
Predicted YTO na na 10.4 8.2 na na
UHDRS TMS 2.0 2.4 2.6 1.3 20.9
a 14.1
UHDRS TFC 12.9 0.2 12.6 0.6 11.3
a 1.9
PBA-s 5.9 1.4 5.0 1.3 13.2
a 3.8
BDI-II 3.9 4.6 5.2 5.5 6.4 6.1
MMSE 29.5 0.7 28.5 1.7 28.3
b 1.6
SDMT 59.2 8.9 48.5 10.8 37.3
d 6.7
TMT-B 46.7 15.1 67.8 27.8 101.4
a 51.2
Stroop II 104.0 15.4 95.1 19.4 79.3
b 19.9
MQ 127.3 11.5 115.5 23.2 99.7
b 13.2
SD Standard deviation, CAG CAG repeat length of larger allele, predicted YTO predicted years to disease onset, UHDRS TMS Uniﬁed
Huntington’s Disease Rating Scale Total Motor Score, PBA-s Problem Behaviour Assessment short version, TFC Total Functional Capacity,
BDI-II Beck Depression Inventory 2nd version, MMSE Mini Mental State Exam, TMT Trail Making Test part B, SDMT Symbol Digit Modality
Test, MQ Memory Quotient, Stroop II Stroop word reading card, na not applicable
a Signiﬁcant differences between manifest HD compared to both premanifest and controls
b Signiﬁcant differences between manifest HD and controls
c Signiﬁcant differences between control and both premanifest and manifest HD
d Signiﬁcant differences between all three groups
e Signiﬁcant difference between premanifest and manifest HD
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123the caudate nucleus, the manifest HD group demonstrated
signiﬁcantly lower NAA (F = 8.12, p = 0.009) and lower
creatine concentration (F = 13.60, p = 0.001) compared
to the control subjects. In the putamen, manifest HD
showed signiﬁcantly lower NAA (F = 5.81, p = 0.024),
lower creatine concentration (F = 5.58, p = 0.027), and
glutamate/glutamine (F = 7.21, p = 0.013) compared to
controls. No signiﬁcant differences were found in the
hypothalamus, thalamus, or prefrontal region. Comparison
of the premanifest gene carrier group and the control group
Fig. 2 Localized proton MR spectra from different regions of the
brain. On the left side the voxel is displayed in the transverse
direction, a typical spectrum of that structure is shown on the right
side for the three groups. Five different regions are displayed:
hypothalamus, thalamus, caudate nucleus, putamen, prefrontal region.
Cho choline, Cr creatine, NAA N-acetylaspartate, mI myo-inositol,
Glx glutamate ? glutamine, Lac lactate, PPM parts per million.
A Gaussian ﬁlter of 4 Hz was applied
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regions. However, the absolute values of NAA, creatine,
and glutamate were lower in the caudate nucleus and
putamen in the premanifest gene carrier group, but did not
reach signiﬁcance.
Relationship to clinical measures
The association of metabolite levels with clinical measures
is shown in Table 3. TFC was associated with creatine
levels in caudate nucleus and putamen and with NAA in the
putamen, showing decreased metabolite levels correspond-
ing to poorer clinical scores. The NAA concentration in the
putamen was associated with higher scores on the UHDRS
TMS, indicating lower NAA to correspond to more motor
disturbances. Lower glutamate/glutamine related to poorer
scores on the cognitive tests SDMT and TMT. Finally, a
higher PBA score, indicating more behavioral disturbances,
corresponded to lower creatine in the caudate nucleus.
Discussion
The major ﬁndings of this study are lower concentrations
of creatine and NAA in the caudate nucleus and the
putamen, and a reduction of glutamate in the putamen in
manifest HD. A relationship between the differences in
these metabolic levels and clinical measures of disease
severity, especially global functioning, was demonstrated.
No statistically signiﬁcant differences in any metabolite
concentration were observed when the premanifest group
was compared to controls, although the absolute lower
values could indicate a subtle decline.
As creatine is considered an important marker for brain
energy metabolism [10], the ﬁnding of lower creatine
levels suggests impaired energy metabolism in manifest
HD. In the healthy population, the concentration of creatine
in the brain is considered to be fairly stable, however,
speciﬁc pathology has been shown to inﬂuence creatine
concentrations [10]. The ﬁnding of lower creatine in
putamen and caudate nucleus is supported by ﬁndings of
Sanchez et al. [25], who observed a reduction of both
creatine and NAA in the striatum. Reynolds et al. [21] went
on to propose creatine as a possible biomarker, when they
demonstrated lower levels in the caudate nucleus in pre-
manifest HD. Contrary to our ﬁndings, Reynolds et al. [21]
did not report altered creatine levels in the putamen.
Results from the TRACK-HD study reported by Sturrock
et al. [27] show similar lower values of creatine in the
putamen as our study. Jenkins et al. [11, 12] found
Fig. 3 LCModel output
example. This ﬁgure depicts the
output provided by the
LCModel analysis. The black
line is the raw spectrum and the
red line is the ﬁt by LCmodel.
PPM parts per million
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displayed by elevated lactate levels in HD within the
occipital cortex. However, our study did not show elevated
lactate in any of the examined structures. This ﬁnding can
possibly be explained by the fact that Jenkins et al. [11]
used a more severely affected HD population with a lower
mean TFC score of 7.3. Moreover, the region analyzed by
Jenkins et al. [11, 12] did not consist of the basal ganglia,
but of the occipital cortex, which is a very metabolically
active area of the cortex and is also severely atrophied in
HD [29]. Although, these studies are not completely
comparable on the basis of methodology and results, they
do all point towards the importance of assessment of
metabolic changes and speciﬁcally the energy metabolism
markers such as creatine.
Table 2 Metabolite concentrations from ﬁve brain regions in HD
Control Premanifest Manifest
n Mean SD n Mean SD n Mean SD
Hypothalamus 11 10 9
Creatine 10.7 2.1 9.4 2.0 9.3 1.7
Choline 3.7 0.7 3.4 0.6 3.3 0.8
NAA 12.1 1.9 11.9 1.5 11.3 2.1
Glx 12.5 3.0 12.0 4.0 11.0 4.8
Myo-inositol 13.4 4.8 12.7 3.1 13.3 2.8
Lactate 1.5 1.0 1.1 1.1 1.0 1.4
Thalamus 14 13 9
Creatine 12.7 3.5 12.8 3.6 12.1 1.6
Choline 3.1 0.8 3.0 0.7 3.1 0.4
NAA 17.8 6.0 15.8 2.6 15.9 1.6
Glu/Gln 14.8 5.1 15.1 3.4 12.8 3.4
Myo-inositol 8.5 4.1 7.3 2.6 9.5 4.4
Lactate 1.1 1.0 0.5 0.7 1.8 0.9
Caudate Nucleus 12 11 5
Creatine 12.5 1.7 11.7 2.2 8.9* 1.2
Choline 3.1 0.7 2.8 0.5 2.6 0.6
NAA 12.1 2.3 10.8 2.0 9.0** 1.1
Glx 15.4 5.2 13.3 5.7 10.8 1.6
Myo-inositol 6.2 1.4 7.1 2.0 7.9 2.0
Lactate 1.2 0.9 1.5 0.9 0.5 0.8
Putamen 13 9 5
Creatine 13.6 2.3 12.1 2.2 10.9* 0.9
Choline 3.4 0.8 3.1 0.5 3.0 0.4
NAA 14.8 1.6 14.4 1.7 12.8* 0.9
Glx 16.3 3.4 14.2 3.4 11.4* 3.8
Myo-inositol 7.3 2.1 6.5 3.1 10.5 4.0
Lactate 0.8 0.6 1.0 1.3 0.3 0.4
Prefrontal 13 9 10
Creatine 9.1 2.4 9.2 1.6 9.9 2.1
Choline 2.3 0.5 2.4 0.4 2.3 0.5
NAA 11.7 2.4 11.6 1.5 11.9 3.0
Glx 11.3 2.8 9.8 2.2 13.3 4.0
Myo-inositol 9.5 2.4 8.8 1.9 11.9 4.9
Lactate 1.2 1.1 1.5 1.5 0.8 0.9
Concentrations of metabolites in the three groups. Since the water concentra-
tion and the T1 and T2 relaxation times of the individual metabolites in the
speciﬁc voxels of interest are unknown at the ﬁeld strength of 7 Tesla, data are
expressed as relative values to the water peak in arbitrary units (AU)
NAA N-acetylaspartate, Glx glutamate ? glutamine
* p\0.05
** p\0.005
Table 3 Relationship of the clinical measures with metabolite con-
centration in the caudate nucleus and putamen
Caudate nucleus Putamen
Creatine NAA Creatine NAA Glx
Disease burden
R -0.266 -0.473 0.168 0.284 -0.400
p 0.339 0.075 0.584 0.347 0.157
UHDRS TMS
R -0.280 -0.228 -0.324 -0.415 -0.255
p 0.157 0.253 0.106 0.035* 0.200
PBA-s
R -0.545 -0.207 -0.063 0.064 0.052
p 0.003* 0.300 0.758 0.754 0.797
TFC
R 0.409 0.106 0.440 0.556 0.095
p 0.034* 0.598 0.025* 0.003* 0.636
BDI-II
R -0.256 -0.022 0.005 0.206 0.152
p 0.197 0.914 0.983 0.323 0.457
MMSE
R -0.196 -0.106 -0.070 -0.108 -0.223
p 0.328 0.598 0.735 0.601 0.265
TMT-B
R 0.310 0.270 0.185 0.049 0.438
p 0.115 0.173 0.366 0.813 0.022*
SDMT
R 0.171 0.133 0.239 0.125 0.555
p 0.404 0.518 0.250 0.552 0.003*
MQ
R 0.151 0.078 -0.049 -0.013 0.326
p 0.451 0.700 0.811 0.951 0.097
Stroop II
R -0.196 -0.106 -0.070 -0.108 -0.223
p 0.328 0.598 0.735 0.601 0.265
Correlation analysis of metabolite concentration with clinical
measures
UHDRS TMS Uniﬁed Huntington’s Disease Rating Scale Total Motor
Score, PBA-s Problem Behaviour Assessment short version, TFC
Total Functional Capacity, BDI-II Beck Depression Inventory 2nd
version, MMSE Mini Mental State Exam, TMT Trail Making Test part
B, SDMT Symbol Digit Modality Test, MQ Memory Quotient, Stroop
II Stroop word reading card, R partial r correlation coefﬁcient,
ppvalue
* p\0.05
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[10] and lower NAA levels suggest a decrease in neuronal
integrity. As atrophy of numerous brain structures is
apparent in manifest HD, it is likely that neurons are
affected and a decrease in NAA may occur. This hypoth-
esis was previously conﬁrmed within the striatum [6, 11,
25]. Again, the recent report from Sturrock et al. [27]i s
similar to our ﬁndings of lower NAA in the putamen. Our
study conﬁrms the ﬁnding of decreased NAA in the stria-
tum (caudate nucleus plus putamen), and more importantly,
our data show that neuronal damage may be present in both
the caudate nucleus and putamen separately. The ability to
acquire spectra from relatively small voxels is an important
advantage of higher magnetic ﬁelds in localized MR
spectroscopy.
Glutamate is of interest in light of the excitotoxicity
theory, which states that an overstimulation of neurons
causes cell damage and eventually cell death. In neurons,
this can occur either due to increased levels of glutamate
(and/or its precursor glutamine) or due to an increase in
sensitivity of the glutamate receptors, both resulting in the
same effect [8, 23]. Taylor et al. described increased levels
of glutamate, supporting this theory [31, 32]. However, the
glutamate levels in these studies were expressed as a ratio
to creatine, and could also be inﬂuenced by changes of the
creatine level. Our study demonstrates reduced glutamate
levels in the putamen. An explanation may be that the
number of viable neurons is decreased to an extent where
glutamate is lowered along with the neuron count. Also, the
sensitivity of glutamate receptors could be altered, result-
ing in altered levels of glutamate. However, without further
investigation, these propositions are highly speculative.
In the premanifest HD group, no changes in any of the
examined metabolites levels could be demonstrated. This
was an unexpected ﬁnding, as previous studies have
reported structural abnormalities, e.g., atrophy, at this stage
[5, 30, 34] and some reports exist of lowered levels of
metabolites in premanifest HD gene carriers [21, 25].
Sanchez-Pernaute et al. [25] did report lower NAA and
lower creatine in the striatum in four premanifest gene
carriers; however, the article already stated that there were
soft motor signs present in two out of four in this group.
Reynolds et al. [21] reported on lower values of creatine,
NAA, yet concluded that there was no pathognomonic
proﬁle in metabolite changes, but stated that there was
great heterogeneity in this respect. Nonetheless, we did
hypothesize that premanifest HD would show altered levels
of metabolites as atrophy (which is already present more
than a decade before disease onset [2, 15, 30, 34]) is log-
ically the result of underlying processes. We must therefore
conclude that either we cannot (yet) measure these changes
or the processes involved are more complex than simple
linear correlation between metabolite levels and disease
severity. For instance, the excitotoxicity theory can possi-
bly be a process measured by increased (damaging effects)
or decreased (loss of healthy neurons) levels of glutamate
depending on the individual disease stage. When per-
forming group analysis, these measurements can become
diluted. Individual assessment of longitudinal changes
could shed more light on these changes. An explanation as
to why no signiﬁcant differences in our premanifest pop-
ulation were found, may be that our premanifest group was
too heterogeneous in terms of proximity to disease onset.
When taking into consideration the ‘‘disease burden
score’’, a proven correlate of striatal damage and thereby
proximity to onset [16], a range of 121.5–450.5 exists
within our premanifest HD sample. This large range sug-
gests a great deal of variability in striatal damage and
therefore of possible metabolite differences. Even so,
despite this large range in disease burden score, a decline in
absolute values of NAA and creatine was observed in the
premanifest group, although this did not reach statistical
signiﬁcance. A second explanation could be our very
stringent inclusion criteria. Only premanifest participants
were included when there was no evidence of motor
symptoms, as quantiﬁed by an UHDRS motor score of 5 or
less, whereas other studies may have allowed participation
of premanifest gene carriers with a higher degree of clinical
abnormalities.
Our data show that metabolite levels are associated with
clinical measures of disease severity. This ﬁnding high-
lights the feasibility of MRS in clinical trails, whereby
metabolite levels could be target outcome measures.
Endeavors using creatine as a treatment for HD with MRS
as a monitoring tool have demonstrated the feasibility of
this method [28].
This study shows the clinical application of high-ﬁeld
7-Tesla MRI. The spectral resolution in combination with
small voxel size and total scanning time is a clear
improvement in MRS methodology [14, 33]. This allows
the examination of metabolites in small, well-deﬁned
anatomical structures, such as the caudate nucleus and
putamen for HD, and can be used in the examination of
many other disorders where spectral and spatial resolution
is of great importance.
A limitation of our study was the fact that the preman-
ifest group was not uniformly distributed according to
expected disease onset, which may have lead to a relatively
large spread of the metabolite concentrations. A more
homogeneous group close to onset could possibly reveal
more signiﬁcant results already in the premanifest stage of
the disease. Also, the small number of participants included
in the manifest groups could be seen as a limitation.
However, despite the small amount of participants, the
results were still signiﬁcant. Furthermore, the hypothala-
mus region (bilaterally) included some CSF in the voxel,
J Neurol (2011) 258:2230–2239 2237
123especially in the manifest HD group, as a result of atrophy,
which could account for the less reliable measurements.
This was not a problem for any of the other regions.
Finally, the frontal region consisted of approximately 50%
of both grey and white matter, which could lead to false-
negative ﬁndings if grey or white matter would be
unequally affected.
In conclusion, in manifest HD, lower NAA was found in
the caudate nucleus and putamen, supporting the theory of
impaired energy metabolism as part of the pathophysiology
of Huntington’s disease. Glutamate levels were lowered in
the putamen, however, to which extent this ﬁnding supports
the excitotoxicity theory remains unclear. The relationship
with clinical measures of function makes MRS a potential
disease monitor and could also possibly be used to evaluate
therapeutics targeted at metabolic processes in HD.
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